These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19895348)

  • 1. Variable expression of soluble fms-like tyrosine kinase 1 in patients at high risk for preeclampsia.
    Dwyer BK; Krieg S; Balise R; Carroll IR; Chueh J; Nayak N; Druzin M
    J Matern Fetal Neonatal Med; 2010 Jul; 23(7):705-11. PubMed ID: 19895348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
    Govender N; Naicker T; Rajakumar A; Moodley J
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women.
    Moore Simas TA; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Maynard SE
    J Matern Fetal Neonatal Med; 2014 Jul; 27(10):1038-48. PubMed ID: 24066977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
    N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria.
    Ohkuchi A; Hirashima C; Matsubara S; Suzuki H; Takahashi K; Usui R; Suzuki M
    Hypertens Pregnancy; 2009 Feb; 28(1):95-108. PubMed ID: 19165674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gestational angiogenic biomarker patterns in high risk preeclampsia groups.
    Maynard SE; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Moore Simas TA
    Am J Obstet Gynecol; 2013 Jul; 209(1):53.e1-9. PubMed ID: 23517919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
    Kim MY; Buyon JP; Guerra MM; Rana S; Zhang D; Laskin CA; Petri M; Lockshin MD; Sammaritano LR; Branch DW; Porter TF; Merrill JT; Stephenson MD; Gao Q; Karumanchi SA; Salmon JE
    Am J Obstet Gynecol; 2016 Jan; 214(1):108.e1-108.e14. PubMed ID: 26432463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal, gestational and neonatal characteristics and maternal angiogenic factors in normotensive pregnancies.
    Staff AC; Harsem NK; Braekke K; Hyer M; Hoover RN; Troisi R
    Eur J Obstet Gynecol Reprod Biol; 2009 Mar; 143(1):29-33. PubMed ID: 19135290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
    Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
    Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.
    Romero R; Nien JK; Espinoza J; Todem D; Fu W; Chung H; Kusanovic JP; Gotsch F; Erez O; Mazaki-Tovi S; Gomez R; Edwin S; Chaiworapongsa T; Levine RJ; Karumanchi SA
    J Matern Fetal Neonatal Med; 2008 Jan; 21(1):9-23. PubMed ID: 18175241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis.
    Kleinrouweler CE; Wiegerinck MM; Ris-Stalpers C; Bossuyt PM; van der Post JA; von Dadelszen P; Mol BW; Pajkrt E;
    BJOG; 2012 Jun; 119(7):778-87. PubMed ID: 22433027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
    Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Tuohey L; Parry LJ; Senadheera S; Illanes SE; Kaitu'u-Lino TJ; Tong S
    Am J Obstet Gynecol; 2016 Mar; 214(3):356.e1-356.e15. PubMed ID: 26721779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia.
    Masuyama H; Nakatsukasa H; Takamoto N; Hiramatsu Y
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2672-9. PubMed ID: 17426083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia.
    Baumann MU; Bersinger NA; Mohaupt MG; Raio L; Gerber S; Surbek DV
    Am J Obstet Gynecol; 2008 Sep; 199(3):266.e1-6. PubMed ID: 18771978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia.
    Thadhani R; Mutter WP; Wolf M; Levine RJ; Taylor RN; Sukhatme VP; Ecker J; Karumanchi SA
    J Clin Endocrinol Metab; 2004 Feb; 89(2):770-5. PubMed ID: 14764795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble endoglin for the prediction of preeclampsia in a high risk cohort.
    Maynard SE; Moore Simas TA; Bur L; Crawford SL; Solitro MJ; Meyer BA
    Hypertens Pregnancy; 2010; 29(3):330-41. PubMed ID: 20670156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors.
    Lim JH; Kim SY; Park SY; Yang JH; Kim MY; Ryu HM
    Obstet Gynecol; 2008 Jun; 111(6):1403-9. PubMed ID: 18515525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
    Powers RW; Jeyabalan A; Clifton RG; Van Dorsten P; Hauth JC; Klebanoff MA; Lindheimer MD; Sibai B; Landon M; Miodovnik M;
    PLoS One; 2010 Oct; 5(10):e13263. PubMed ID: 20948996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia.
    Leaños-Miranda A; Campos-Galicia I; Ramírez-Valenzuela KL; Chinolla-Arellano ZL; Isordia-Salas I
    Hypertension; 2013 May; 61(5):1118-25. PubMed ID: 23460287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.